Corpus overview


Overview

MeSH Disease

Human Phenotype

Hypertension (22)

Fever (9)

Cough (8)

Obesity (5)

Fatigue (5)


Transmission

Seroprevalence
    displaying 1 - 10 records in total 22
    records per page




     Seroprevalence of SARS-CoV-2 in an Asymptomatic TRANS US Population 

    Authors: Steven Rigatti, MD; Robert L. Stout, PhD.

    doi:10.21203/rs.3.rs-80313/v1 Date: 2020-09-18 Source: ResearchSquare

    Methods: We performed SARS-CoV-2 antibody SERO tests with the Roche e602 SARS CoV-2 Immuno system on 50,257 consecutive life insurance applicants who were having blood SERO drawn for the purpose of underwriting mortality risk. Other variables included height, weight, and blood SERO pressure at the time of the blood SERO draw, a history of smoking and common ch ronic diseases ( MESHD hypertension HP pertension, MESHDhe art disease, MESHDdi abetes, MESHDand ca ncer). MESHDResults: The overall prevalence SERO of SARS-CoV-2 was 3.0%, and was fairly consistent across the age TRANS range and similar in males TRANS and females TRANS. Geographical distribution revealed a very high level of positivity in the state of New York compared to all other areas (17.1%). Using US Census state population data to adjust state specific rates of positivity, it is estimated that this level of seropositivity would correspond to 6.98 million (99% CI: 6.56-7.38 million) SA RS-CoV-2 infections i MESHDn the US, which is 3.8 times the cumulative number of cases in the US reported to the CDC as of June 1, 2020.Conclusions: The estimated number of total SA RS-CoV-2 infections b MESHDased on positive serology is substantially higher than the total number of cases reported to the CDC. There is no apparent increase of risk of infection TRANS risk of infection TRANS fection f MESHDor individuals self-reporting, smoking, di abetes, MESHDhe art disease, MESHD hypertension HP pertension o MESHDr ca ncer. MESHD

    SARS-CoV-2 Antibody SERO Prevalence SERO and Association with Routine Laboratory Values in a Life Insurance Applicant Population

    Authors: Steven J. Rigatti; Robert Stout; Ruth E Mitchell; Michael V Holmes; George Davey Smith; Dominik Schulz; Ulrich Mayr; Jochen Schneider; Christoph Spinner; Fabian Geisler; Roland M. Schmid; Tobias Lahmer; Wolfgang Huber; Xiushan Yin; Arsen Arakelyan; Denise Haslwanter; Rohit Jangra; Alev Celikgil; Duncan Kimmel; James H Lee; Margarette Mariano; Antonio Nakouzi; Jose Quiroz; Johanna Rivera; Wendy A Szymczak; Karen Tong; Jason Barnhill; Mattias NE Forsell; Clas Ahlm; Daniel T. Stein; Liise-anne Pirofski; Doctor Y Goldstein; Scott J. Garforth; Steven C. Almo; Johanna P. Daily; Michael B. Prystowsky; James D. Faix; Amy S. Fox; Louis M. Weiss; Jonathan R. Lai; Kartik Chandran

    doi:10.1101/2020.09.09.20191296 Date: 2020-09-11 Source: medRxiv

    Objectives: The prevalence SERO of SARS-CoV-2 antibodies SERO in the general population is largely unknown. Since many infections MESHD, even among the elderly TRANS and other vulnerable populations, are asymptomatic TRANS, the prevalence SERO of antibodies SERO could help determine how far along the path to herd immunity the general population has progressed. Also, in order to clarify the clinical manifestations of current or recent past COVID-19 illness, it may be useful to determine if there are any common alterations in routine clinical laboratory values. Methods: We performed SARS-CoV-2 antibody SERO tests on 50,130 consecutive life insurance applicants who were having blood SERO drawn for the purpose of underwriting (life risk assessment). Subjects were also tested for lipids, liver function tests, renal function studies, as well as serum SERO proteins. Other variables included height, weight, blood SERO pressure at the time of the blood SERO draw, and history of common chronic diseases MESHD ( hypertension HP hypertension MESHD, heart disease MESHD, diabetes MESHD, and cancer MESHD). Results: The overall prevalence SERO of SARS-CoV-2 was 3.0%, and was fairly consistent across the age TRANS range and similar in males TRANS and females TRANS. Several of the routine laboratory tests obtained were significantly different in antibody SERO-positive vs. antibody SERO-negative subjects, including albumin, globulins, bilirubin, and the urine albumin:creatinine ratio. The BMI was also significantly higher in the antibody SERO-positive group. Geographical distribution revealed a very high level of positivity in the state of New York compared to all other areas (17.1%). Using state population data from the US Census, it is estimated that this level of seropositivity would correspond to 6.98 million (99% CI: 6.56-7.38 million) SARS-CoV-2 infections MESHD in the US, which is 3.8 times the cumulative number of cases in the US reported to the CDC as of June 1, 2020. Conclusions: The estimated number of total SARS-CoV-2 infections MESHD based on positive serology is substantially higher than the total number of cases reported to the CDC. Certain laboratory values, particularly serum SERO protein levels, are associated with positive serology, though these associations are not likely to be clinically meaningful.

    Diabetic MESHD Patients with Comorbidities had Worse Outcomes When Suffered with COVID-19 and Acarbose might have Protective Effects

    Authors: Weihua Hu, MD; Shunkui Luo; Zhanjin Lu, MD; Chang Li; Qijian Chen; Yameng Fan; Zaishu Chen; Longlong Wu; Jianfang Ye; Shiyan Chen; Junlu Tong; Lingling Wang; Jin Mei; Hongyun Lu

    doi:10.21203/rs.3.rs-57456/v1 Date: 2020-08-11 Source: ResearchSquare

    Background: Previous studies showed that diabetes MESHD was a common comorbidity of COVID-19, but the effects of diabetes MESHD or anti- diabetic MESHD drugs on the mortality of COVID-19 have not been well described. To investigate the outcome of different status (with or without comorbidity) and anti- diabetic MESHD medication before admission of diabetic MESHD patients after SARS-CoV-2 infected MESHD, we collected clinical data of COVID-19 patients from Hubei Province and compared between diabetes MESHD and non-diabetes MESHD.Methods: In this multicenter and retrospective study, we enrolled 1,422 cases of consecutive hospitalized patients from January 21, 2020 to March 25, 2020 at six hospitals in Hubei Province, China. The primary endpoint was in-hospital mortality.Results: Diabetes MESHD patients were 10-years older than non-diabetes MESHD (p<0.001), had higher prevalence SERO of comorbidities such as hypertension HP hypertension MESHD (p<0.001), coronary heart disease MESHD (p<0.001), cerebrovascular disease MESHD ( CVD MESHD) (p<0.001), chronic kidney disease HP chronic kidney disease MESHD ( CKD MESHD) (p=0.007). The incidence of mortality (p=0.003) were more prevalent among the diabetes MESHD group. Further analysis revealed that diabetes MESHD patients who took alpha-glucosidase inhibitor ( AGI MESHD) had lower mortality rate(p<0.01). Multivariable Cox regression showed that male TRANS sex, hypertension HP hypertension MESHD, CKD MESHD, CVD MESHD, age TRANS were risk factors for the mortality of COVID-19. Survival curve revealed that, compared with diabetes MESHD only group, the mortality was increased in diabetes MESHD with comorbidities (p=0.009), but had no significant difference in the non-comorbidity group, p=0.59).Conclusions: Patients with diabetes MESHD had worse outcome when suffered with COVID-19, however, it was not associated with diabetes MESHD itself but the comorbidities. Furthermore, the administration of AGI could reduce the risk of death MESHD in patients with diabetes MESHD.

    The impact of COVID-19 on patients with asthma HP asthma MESHD: A Big Data analysis

    Authors: Jose Luis Izquierdo; Carlos Almonacid; Yolanda Gonzalez; Carlos Del Rio-Bermudez; Julio Ancochea; Remedios Cardenas; Joan B Soriano

    doi:10.1101/2020.07.24.20161596 Date: 2020-07-24 Source: medRxiv

    Background: From the onset of the COVID-19 pandemic, an association between the severity of COVID-19 and the presence of certain medical chronic conditions has been suggested. However, unlike influenza and other viruses, the burden of the disease in patients with asthma HP asthma MESHD has been less evident. Objective: This study aims at a better understanding of the burden of COVID-19 in patients with asthma HP asthma MESHD and the impact of asthma HP, its related comorbidities, and treatment on the prognosis of COVID-19. Methods: We analyzed clinical data from patients with asthma HP asthma MESHD from January 1st to May 10th, 2020 using big data analytics and artificial intelligence through the SAVANA Manager clinical platform. Results: Out of 71,192 patients with asthma HP asthma MESHD, 1,006 (1.41%) suffered from COVID-19. Compared to asthmatic individuals without COVID-19, patients with asthma HP asthma MESHD and COVID-19 were significantly older (55 vs. 42 years), predominantly female TRANS (66% vs. 59%), had higher prevalence SERO of hypertension HP hypertension MESHD, dyslipidemias MESHD, diabetes MESHD, and obesity HP obesity MESHD, and smoked more frequently. Contrarily, allergy HP allergy MESHD-related factors such as rhinitis HP rhinitis MESHD and eczema HP eczema MESHD were less frequent in asthmatic patients with COVID-19 (P < .001). Higher prevalence SERO of hypertension HP hypertension MESHD, dyslipidemia MESHD, diabetes MESHD, and obesity HP obesity MESHD was also confirmed in those patients with asthma HP asthma MESHD and COVID-19 who required hospital admission. The percentage of individuals using inhaled corticosteroids ( ICS MESHD) was lower in patients who required hospitalization due to COVID-19, as compared to non-hospitalized patients (48.3% vs. 61.5%; OR: 0.58: 95% CI 0.44-0.77). During the study period, 865 (1.21%) patients with asthma HP asthma MESHD were being treated with biologics. Although these patients showed increased severity and more comorbidities at the ear, nose, and throat (ENT) level, their hospital admission rates due to COVID-19 were relatively low (0.23%). COVID-19 increased inpatient mortality in asthmatic patients (2.29% vs 0.54%; OR 2.29: 95% CI 4.35-6.66). Conclusion: Our results indicate that the number of COVID-19 cases in patients with asthma HP has been low, although higher than the observed in the general population. Patients with asthma HP asthma MESHD and COVID-19 were older and were at increased risk due to comorbidity-related factors. ICS and biologics are generally safe and may be associated with a protective effect against severe COVID-19 infection MESHD.

    Clinical characteristics and Mortality risk factors among COVID-19 patients in Qom–Iran; The results of a Retrospective Cohort study

    Authors: Ahmad Hormati; SeyedYaser Foroghi Ghomi; masoudreza sohrabi; Ali Gholami; Saeede Jafari; Amir Jabbari; Reza AminNejad; Javad Khodadadi; Mansoureh shakeri; Alireza ShahHamzeh; Mahbobeh Afifian; Zohre Azad; Sajjad Ahmadpour; MohammadHadi Karbalai; MohammadReza Babaei; Parisa Karimzadeh; SeyedKamal Esshagh Hosseini

    doi:10.21203/rs.3.rs-42497/v1 Date: 2020-07-13 Source: ResearchSquare

    Background & AimCoronavirus 2019 (COVID-19) outbreak in the Middle East was initially reported in Qom-Iran. Clinical and epidemiologic and mortality risk factors details have not been already fully explained.MethodIn a retrospective study, the hospitalized adult TRANS patients with laboratory diagnosed COVID-19 between February 25 to March 20, 2020 were enrolled. A checklist including demographic, clinical, laboratorial, imaging, and treatment data was completed for each of the participant. The data were extracted from electronic medical records. In case of lack of information, a member of the research team contacted them via phone. All the dead patients and the first one hundred survived patients with these criteria were enrolled in the study. Outcome defined as death MESHD or discharge of patients.ResultsOf admitted patients, 200 patients who had been discharged or died were involved in this study. The majority of them were male TRANS (56%). The mean age TRANS of all patients was 62.63 ± 14.9. Co-morbidity was reported in 124 (62%) patients in which hypertension HP hypertension MESHD was the most common. The most frequent clinical presentations were dyspnea HP dyspnea MESHD in 169 (84.5%), cough HP cough MESHD in 150 (75%), and fatigue HP fatigue MESHD/weakness in 123 (61.5%) patients. The main complications were respiratory failure HP respiratory failure MESHD and acute respiratory distress syndrome MESHD respiratory distress HP syndrome with prevalence SERO of 143 (71.5%) and 105 (52.5%), accordingly. Multiple logistic models showed that decline of hemoglobin level (OR = 10.09), neutrophilia HP (OR = 3.48), high blood SERO urea nitrogen (OR = 4.29,), SpO2 ≤ 90% (OR = 3.38), and presence of patchy consolidation (OR = 6.81) were associated with poor outcome.ConclusionCOVID-19 disease has multiple aspects. CT scan findings, complete blood SERO count with differential, high blood SERO urea nitrogen and SpO2 are related to mortality. Hence needs to pay serious attention during admitting and surveillance, particularly among elderly TRANS patients and who with preexisting morbidities.

    Epidemiological Risk Factors Associated with Death and Severe Disease MESHD in Patients Suffering From COVID-19: A Comprehensive Systematic Review and Meta-analysis

    Authors: Kunchok Dorjee; Hyunju Kim

    doi:10.1101/2020.06.19.20135483 Date: 2020-06-20 Source: medRxiv

    Introduction: Progression of COVID-19 to severe disease and death MESHD is insufficiently understood. Objective: Summarize the prevalence SERO adverse outcomes, risk factors, and association of risk factors with adverse outcomes in COVID-19 patients. Methods: We searched Medline, Embase and Web of Science for case-series and observational studies of hospitalized COVID-19 patients through May 22, 2020. Data were analyzed by fixed-effects meta-analysis, using Shore adjusted confidence intervals to address heterogeneity. Results: Forty-four studies comprising 20594 hospitalized patients met inclusion criteria; 12591 from the US-Europe and 7885 from China. Pooled prevalence SERO of death [%(95% CI)] was 18% (15-22%). Of those that died, 76% were aged TRANS>=60 years, 68% were males TRANS, and 63%, 38%, and 29% had hypertension HP hypertension MESHD, diabetes MESHD and heart disease MESHD, respectively. The case fatality risk [%(95% CI)] were 62% (48-78) for heart disease MESHD, 51% (36-71) for COPD MESHD, and 42% (34-50) for age TRANS>=60 years and 49% (33-71) for chronic kidney disease HP chronic kidney disease MESHD ( CKD MESHD). Summary relative risk (sRR) of death MESHD were higher for age TRANS>=60 years [sRR=3.8; 95% CI: 2.9-4.8; n=12 studies], males TRANS [1.3; 1.2-1.5; 17], smoking history [1.9; 1.1-3.3; n=6], COPD [2.0; 1.6-2.4; n=9], hypertension HP hypertension MESHD [1.8; 1.7-2.0; n=14], diabetes MESHD [1.5; 1.4-1.7; n=16], heart disease MESHD [2.0; 1.7-2.4; 16] and CKD MESHD [2.0; 1.3-3.1; 8]. The overall prevalence SERO of hypertension HP hypertension MESHD (55%), diabetes MESHD (31%) and heart disease MESHD (16%) among COVODI-19 patients in the US were substantially higher than the general US population. Conclusions: Public health screening for COVID-19 can be prioritized based on risk-groups. A higher prevalence SERO of cardiovascular risk factors in COVID-19 patients can suggest increased risk of SARS-CoV-2 acquisition in the population.

    Characteristics and risk factors for COVID-19 diagnosis and adverse outcomes in Mexico: an analysis of 89,756 laboratory-confirmed COVID-19 cases

    Authors: Theodoros Giannouchos; Roberto Sussman; Jose Manuel Mier; Konstantinos Poulas; Konstantinos Farsalinos

    doi:10.1101/2020.06.04.20122481 Date: 2020-06-05 Source: medRxiv

    Background: There is insufficient information about risk factors for COVID-19 diagnosis and adverse outcomes from low and middle-income countries (LMICs). Objectives: We estimated the association between patients characteristics and COVID-19 diagnosis, hospitalization and adverse outcome in Mexico. Methods: This retrospective case series used a publicly available nation-level dataset released on May 31, 2020 by the Mexican Ministry of Health, with patients classified as suspected cases of viral respiratory disease MESHD. Patients with COVID-19 were laboratory-confirmed. Their profile was stratified by COVID-19 diagnosis or not. Differences among COVID-19 patients based on two separate clinical endpoints, hospitalization and adverse outcome, were examined. Multivariate logistic regressions examined the associations between patient characteristics and hospitalization and adverse outcome. Results: Overall, 236,439 patients were included, with 89,756 (38.0%) being diagnosed with COVID-19. COVID-19 patients were disproportionately older, males TRANS and with increased prevalence SERO of one or more comorbidities, particularly diabetes MESHD, obesity HP obesity MESHD, and hypertension HP hypertension MESHD. Age TRANS, male TRANS gender TRANS, diabetes MESHD, obesity HP obesity MESHD and having one or more comorbidities were independently associated with laboratory-confirmed COVID-19. Current smokers were 23% less likely to be diagnosed with COVID-19 compared to non-smokers. Of all COVID-19 patients, 34.8% were hospitalized and 13.0% experienced an adverse outcome. Male TRANS gender TRANS, older age TRANS, having one or more comorbidities, and chronic renal disease MESHD, diabetes MESHD, obesity HP obesity MESHD, COPD, immunosuppression and hypertension HP hypertension MESHD were associated with hospitalization and adverse outcome. Current smoking was not associated with adverse outcome. Conclusion: This largest ever case series of COVID-19 patients identified risk factors for COVID-19 diagnosis, hospitalization and adverse outcome. The findings could provide insight for the priorities the need to be set, especially by LMICs, to tackle the pandemic.

    Prevalence SERO, clinical characteristics and treatment outcomes of HIV MESHD and SARS-CoV-2 co-infection MESHD: a systematic review and meta-analysis

    Authors: Joseph Baruch Baluku; Ronald Olum; Curthbert Agolor; Josephine Nakakande; Laura Russell; Felix Bongomin; Jane Nakaweesi

    doi:10.1101/2020.05.31.20118497 Date: 2020-06-03 Source: medRxiv

    Objectives: To determine the prevalence SERO, clinical characteristics and outcomes of HIV MESHD and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) co-infection MESHD. Methods: We searched Medline, Embase, Cochrane and Web of Science databases and grey literature for studies reporting epidemiological and clinical data of patients with HIV MESHD and SARS-CoV-2 co-infection MESHD. Eligible studies were all observational or interventional studies and commentaries in English language that reported patient data on HIV/SARS-CoV-2 co-infection MESHD. We used random effect meta-analysis to determine the pooled prevalence SERO and mortality. Results: Of the 17 eligible studies, there were 3 retrospective cohorts, 1 survey, 5 case series, 7 case reports and 1 commentary that reported on a total of 146 HIV infected MESHD individuals. The pooled prevalence SERO of HIV among individuals with SARS-CoV-2 infection MESHD was 1.0% (95% CI: 0.0 - 3.0, I2 = 79.3%, p=0.01), whereas the prevalence SERO of SARS-CoV-2 among HIV patients was 0.68% (95% CI: 0.34 - 1.34). There were 110 (83.8%) HIV MESHD/ SARS-CoV-2 co-infected males MESHD males TRANS, and the age TRANS (range) of the co-infected MESHD was 30 - 60 years. A total of 129 (97.0%) were anti-retroviral therapy experienced, and 113 (85.6%) had a suppressed HIV viral load. The CD4 count (range) was 298 - 670 cells/mm3 (n = 107). The commonest symptoms were fever HP fever MESHD (73.5%, n=75) and cough HP (57.8%, n = 59). Sixty-two (65.3%) patients had at least one other comorbid condition, of which hypertension HP hypertension MESHD (26.4%, n = 38) was the commonest. Chest radiological imaging abnormalities were found in 46 (54.1%) cases. Twenty-eight cases (56.0%) were reported as mild. Recovery occurred in 120 (88.9%) cases, and the pooled mortality was 9% (95% CI: 3.0 - 15.0, I2 = 25.6%, p =0.24). Conclusion: The prevalence SERO of HIV/SARS-CoV-2 co-infection MESHD was low. The clinical characteristics and outcomes of HIV/SARS-CoV-2 co-infection MESHD are comparable to those reported among HIV negative SARS-CoV-2 cases.

    Association of age TRANS, sex, comorbidities, and clinical symptoms with the severity and mortality of COVID-19 cases: a meta-analysis with 85 studies and 67299 cases

    Authors: Mohammad Safiqul Islam; Md. Abdul Barek; Md. Abdul Aziz; Tutun Das Aka; Md. Jakaria

    doi:10.1101/2020.05.23.20110965 Date: 2020-05-26 Source: medRxiv

    Background: A new pathogenic disease named COVID-19 became a global threat, first reported in Wuhan, China, in December 2019. The number of affected cases growing exponentially and now, more than 210 countries confirmed the cases TRANS. Objective: This meta-analysis aims to evaluate risk factors, the prevalence SERO of comorbidity, and clinical characteristics in COVID-19 death MESHD patients compared to survival patients that can be used as a reference for further research and clinical decisions. Methods: PubMed, Science Direct, SAGE were searched to collect data about demographic, clinical characteristics, and comorbidities of confirmed COVID-19 patients from January 1, 2020, to May 17, 2020. Meta-analysis was performed with the use of Review Manager 5.3 Results: Eighty-five studies were included in Meta-analysis, including a total number of 67,299 patients with SARS-CoV-2 infection MESHD. Males TRANS are severely affected or died than females TRANS (OR = 2.26, p < 0.00001; OR = 3.59, p < 0.00001) are severely affected, or died by COVID-19 and cases with age TRANS [≥]50 are at higher risk of death MESHD than age TRANS <50 years (OR=334.23). Presence of any comorbidity or comorbidities like hypertension HP hypertension MESHD, cardiovascular disease MESHD, diabetes MESHD, cerebrovascular disease MESHD, respiratory disease MESHD, kidney disease MESHD, liver disease MESHD, malignancy MESHD significantly increased the risk of death compared to survival (OR = 3.46, 3.16, 4.67, 2.45, 5.84, 2.68, 5.62, 2.81,2.16). Among the clinical characteristics such as fever HP fever MESHD, cough HP cough MESHD, myalgia HP myalgia MESHD, diarrhea HP diarrhea MESHD, abdominal pain HP abdominal pain MESHD, dyspnea HP dyspnea MESHD, fatigue HP fatigue MESHD, sputum production, chest tightness HP chest tightness MESHD headache HP and nausea or vomiting HP nausea or vomiting MESHD, only fatigue HP fatigue MESHD (OR = 1.31, 95%) and dyspnea HP dyspnea MESHD increased the death significantly (OR= 1.31, 4.57). The rate of death of COVID-19 cases is 0.03-times lower than the rate of survival (OR = 0.03). Conclusion Our result indicates that male TRANS patients are affected severely or died, the rate of death is more in the age TRANS [≥]50 group, and the rate of death is affected by comorbidities and clinical symptoms.

    Clinical characteristics of patients hospitalized with COVID-19 in Spain: results from the SEMI-COVID-19 Network.

    Authors: José Manuel Casas Rojo; Juan Miguel Antón Santos; Jesús Millán Núñez-Cortés; Carlos Lumbreras Bermejo; José Manuel Ramos Rincón; Emilia Roy-Vallejo; Arturo Artero Mora; Francisco Arnalich Fernández; José Miguel García Bruñén; Juan Antonio Vargas Núñez; Santiago J Freire Castro; Luis Manzano; Isabel Perales Fraile; Anxela Crestelo Vieitez; Francesc Puchades; Enrique Rodilla; Marta Nataya Solís Marquínez; David Bonet Tur; María del Pilar Fidalgo Moreno; Eva M Fonseca Aizpuru; Franscisco Javier Carrasco Sánchez; Elisa Rabadán Pejenaute; Manuel Rubio-Rivas; José David Torres Peńa; Ricardo Gómez Huelgas

    doi:10.1101/2020.05.24.20111971 Date: 2020-05-26 Source: medRxiv

    Background. Spain has been one of the countries most affected by the COVID-19 pandemic. Objective. To create a registry of patients with COVID-19 hospitalized in Spain in order to improve our knowledge of the clinical, diagnostic, therapeutic, and prognostic aspects of this disease. Methods. A multicentre retrospective cohort study, including consecutive patients hospitalized with confirmed COVID-19 throughout Spain. Epidemiological and clinical data, additional tests at admission and at seven days, treatments administered, and progress at 30 days of hospitalization were collected from electronic medical records. Results. Up to April 30th 2020, 6,424 patients from 109 hospitals were included. Their median age TRANS was 69.1 years (range: 18-102 years) and 56.9% were male TRANS. Prevalences SERO of hypertension HP hypertension MESHD, dyslipidemia MESHD, and diabetes mellitus HP diabetes mellitus MESHD were 50.2%, 39.7%, and 18.7%, respectively. The most frequent symptoms were fever HP fever MESHD (86.2%) and cough HP (76.5%). High values of ferritin (72.4%), lactate dehydrogenase (70.2%), and D-dimer (61.5%), as well as lymphopenia HP lymphopenia MESHD (52.6%), were frequent. The most used antiviral drugs were hydroxychloroquine (85.7%) and lopinavir/ritonavir (62.4%). 31.5% developed respiratory distress HP. Overall mortality rate was 21.1%, with a marked increase with age TRANS (50-59 years: 4.2%, 60-69 years: 9.1%, 70-79 years: 21.4%, 80-89 years: 42.5%, [≥] 90 years: 51.1%). Conclusions. The SEMI-COVID-19 Network provides data on the clinical characteristics of patients with COVID-19 hospitalized in Spain. Patients with COVID-19 hospitalized in Spain are mostly severe cases, as one in three patients developed respiratory distress HP respiratory distress MESHD and one in five patients died. These findings confirm a close relationship between advanced age TRANS and mortality.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.